2025 Q4: Key Takeaways- Two gene therapy approvals and one RNA therapy approval took place.
- Throughout 2025, the total number of gene, cell, and RNA therapies in development declined, driven by a shift away from preclinical programs.
- Advanced molecular therapy start-up financing continued its quarterly upward trend, reaching 14 transactions in Q4 2025 together worth $557.1 million, a 27% increase in volume and 141% increase in value compared with the previous quarter.
Q3The third quarter of 2025 brought notable progress across the gene, cell, and RNA therapy landscape, marked by four new global approvals — one in each major therapeutic category.
|
